PRESS RELEASE |
INFLAVOBIOTICS Project from BioActor receives grant from CROSSROADS-Programme
MAASTRICHT, March 19, 2018
BioActor receives CROSSROADS grant to further strengthen clinical and mechanistic data around MicrobiomeX, its first in class ‘flavobiotic’.
BioActor recently started the ‘INFLAVOBIOTICS project, a project in collaboration with Prodigest, financed with a grant from the CROSSROADS programme. CROSSROADS is an innovation stimulation programme within the Interreg V programme Flanders-Netherlands.
The ‘INFLAVOBIOTICS’ project aims to develop an innovative medical food/nutraceutical to control inflammatory bowel conditions and associated gut dysbiosis by optimizing the gut microbiota and the connected immune system.
The project has two main aims; the first general aim of this project is to investigate the effect of a citrus flavonoid extract on different markers for gut health both under tightly controlled and relevant in-vitro conditions and provide proof of concept in human volunteers. The second general aim of this project is to investigate several cell lines and their suitability for induced chronic inflammatory conditions and associated dysbiosis at the level of the microbiota.
Within the research consortium, BioActor is spearheading the clinical development plan and ProDigest is focussing on the in-vitro research on the impact of citrus flavonoids on the gut microbiota.
The project will further strengthen the science behind MicrobiomeX, BioActor’s first in class ‘flavobiotic’.
BioActor, based in Maastricht, Netherlands, is a product development company that develops and markets proprietary Active Nutritional ingredients to the nutrition & healthcare industry. The company has two development platforms, one focussing on healthy ageing and another on active living. The goal is to provide the nutrition & healthcare industry with science-based innovations that confer a real health benefit to the consumer.
For further information, please contact:
BIOACTOR, Hans van der Saag, CEO
Tel : + 31 6 1173 4108
E-mail : hans.vandersaag@BIOACTOR.com